Search

Boehringer Ingelheim and Zealand Pharma Advance Dual-Acting GLP-1/glucagon Agonist BI 456906 to Phase 2 Clinical Testing in Obesity/Diabetes

Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio

Introducing Ingelvac Provenza™ | Boehringer Ingelheim US

Find out more on our new swine vaccine, offering increased protection against influenza strains affecting 70% of growing pigs annually.

PDF Download: Heartworm Disease in Dogs | Boehringer Ingelheim US

View our PDF download options on information on heartworm disease in dogs. Find out everything you need to know on prevention, symptoms and treatment.

Financial health

We constantly review our salaries to make sure they stay competitive in each market but we also provide wider support for financial health.

Dominik Huber

Dominik Huber, Our Head of Upstream Manufacturing in Vienna, Dominik Huber, has built his entire, senior-level career with Boehringer Ingelheim.

Nelli Milosch

Nelli Milosch, a team lead for our field-based medical team in Germany, says that the people is the best thing about working in Boehringer Ingelheim.

Heartworm Disease Prevention Initiative | Boehringer Ingelheim USheartworm disease prevention through its Heartworm 2020 initiative

Read more on how the Boehringer Ingelheim heartworm disease prevention initiative has helped more than 51,000 dogs receive care across the USA in 2020.

We support non-linear career paths.

Emmanuelle Clerisme-Beaty talks about making breakthroughs in the rare disease space.“I’m here to let patients know that they're not alone”

Partnering for Innovative Pet Therapeutics

ATS Announces that BI is First Donor of COVID-19 Fund | Boehringer Ingelheim US

American Thoracic Society Announces that Boehringer Ingelheim is the first donor of its COVID‐19 Crisis Fund

Boehringer Ingelheim launches vaccine to protect poultry from three diseases

Boehringer Ingelheim Partners with Express Scripts on their Patient Assurance Program Expansion for People with Type 2 Diabetes

Pushing for Progress

Candice is moving to Germany

Are you considering a career at Boehringer Ingelheim? Find out why Candice loves working here. For more talent insights, visit our Careers Page.

Sanofi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017

First Half of 2022: Boehringer Ingelheim continues growth pace and strengthens research pipeline

Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline

Boehringer Ingelheim today announced a strong acceleration of its pipeline in 2023, as pivotal trials in key research areas progressed as planned.

Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD Therapeutics

Numab Therapeutics and Boehringer Ingelheim Enter into Collaboration to Develop Multi-specific Antibody Therapeutics for Cancer and Retinal Diseases

From garage start-up to global pharma: combining strengths to advance regenerative medicine

Article describing how a strategic partnership between Global Stem Cell and Boehringer Ingelheim Animal Health has played a key role in helping the companies accelerate breakthroughs in regenerative medicine.

Cyltezo® (adalimumab-adbm) Patent Litigation Resolution| BI US

Read more about Boehringer Ingelheim's CYLTEZO patent litigation resolution, meaning greater access to the treatment for patients across the USA.

Boehringer Ingelheim and OSE Immunotherapeutics Announce Dosing Of the First Patient in a Phase 1 Trial of SIRPα Antagonist Monoclonal Antibody, BI 765063, in Patients with Advanced Solid Tumors

Boehringer Ingelheim Partners with Inflammasome Therapeutics to Develop Novel Therapies for Patients with Retinal Diseases

Recognized as an inclusive workplace for the fifth time

Recognized as an Inclusive Workplace for the Fifth Time

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers